ELISEI, ROSSELLA
 Distribuzione geografica
Continente #
NA - Nord America 23.508
EU - Europa 14.240
AS - Asia 3.382
AF - Africa 606
SA - Sud America 73
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 18
Totale 41.848
Nazione #
US - Stati Uniti d'America 22.939
IT - Italia 3.740
DE - Germania 3.159
SE - Svezia 2.845
CN - Cina 1.718
BG - Bulgaria 1.146
AT - Austria 983
GB - Regno Unito 864
CA - Canada 548
TR - Turchia 447
VN - Vietnam 416
CI - Costa d'Avorio 388
UA - Ucraina 376
SG - Singapore 343
FI - Finlandia 297
RU - Federazione Russa 228
BE - Belgio 195
SN - Senegal 185
IN - India 182
CH - Svizzera 133
HK - Hong Kong 126
FR - Francia 68
NL - Olanda 51
BR - Brasile 33
GR - Grecia 26
PL - Polonia 26
JP - Giappone 25
KR - Corea 23
IR - Iran 21
ES - Italia 20
CZ - Repubblica Ceca 18
AU - Australia 17
EU - Europa 17
ID - Indonesia 16
CL - Cile 15
IL - Israele 13
RO - Romania 13
IE - Irlanda 10
MX - Messico 10
NG - Nigeria 10
TW - Taiwan 10
HU - Ungheria 9
PK - Pakistan 9
RS - Serbia 9
CR - Costa Rica 6
MA - Marocco 6
PH - Filippine 6
SK - Slovacchia (Repubblica Slovacca) 6
CO - Colombia 5
DK - Danimarca 5
MG - Madagascar 5
AR - Argentina 4
EG - Egitto 4
MY - Malesia 4
NZ - Nuova Zelanda 4
PE - Perù 4
SV - El Salvador 4
AZ - Azerbaigian 3
BO - Bolivia 3
BY - Bielorussia 3
CY - Cipro 3
EC - Ecuador 3
EE - Estonia 3
NO - Norvegia 3
TH - Thailandia 3
VE - Venezuela 3
BH - Bahrain 2
DZ - Algeria 2
GE - Georgia 2
MN - Mongolia 2
SA - Arabia Saudita 2
UY - Uruguay 2
ZA - Sudafrica 2
A1 - Anonimo 1
AE - Emirati Arabi Uniti 1
AO - Angola 1
BD - Bangladesh 1
GT - Guatemala 1
HR - Croazia 1
IS - Islanda 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LY - Libia 1
MT - Malta 1
MU - Mauritius 1
PT - Portogallo 1
PY - Paraguay 1
SC - Seychelles 1
Totale 41.848
Città #
Woodbridge 2.876
Fairfield 2.816
Chandler 2.125
Ann Arbor 1.995
Houston 1.901
Ashburn 1.527
Seattle 1.228
Sofia 1.145
Milan 1.062
Wilmington 1.055
Cambridge 969
Vienna 789
New York 748
Beijing 693
Princeton 522
Ottawa 516
Lawrence 446
Jacksonville 439
Abidjan 388
Medford 360
Izmir 353
Serra 348
Des Moines 278
Nanjing 266
Florence 202
London 199
Dearborn 191
Brussels 190
Dong Ket 188
Dakar 185
Pisa 167
San Diego 165
Frankfurt am Main 141
Rome 140
Boulder 133
Bern 120
Bremen 119
Hong Kong 111
Redwood City 108
Nanchang 100
Jüchen 78
Kunming 70
Washington 68
Lancaster 63
Düsseldorf 60
Tianjin 59
Changsha 56
Kocaeli 54
Hebei 53
Nürnberg 52
Redmond 51
Shenyang 51
Norwalk 50
Jiaxing 49
Shanghai 41
Falls Church 36
Hefei 36
Detroit 35
Hangzhou 32
Zhengzhou 30
Grafing 27
Jinan 27
Pune 27
Naples 26
Chicago 25
Vicopisano 25
Phoenix 24
Guangzhou 22
Istanbul 22
Boardman 21
Verona 21
Auburn Hills 20
Sacile 19
Singapore 19
Bologna 18
Munich 18
Chengdu 17
Indiana 16
Los Angeles 16
Orange 16
Marseille 15
Napoli 15
Ningbo 15
San Francisco 15
Boydton 14
Poltava 14
Tappahannock 14
Toronto 14
Trieste 14
Wuhan 14
Bengaluru 13
Tokyo 13
Scandicci 12
Chiesina Uzzanese 11
Dallas 11
Jaboatão 11
Turin 11
Kilburn 10
Lagos 10
Lanzhou 10
Totale 29.010
Nome #
I CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE HANNO ORIGINE GENETICA INDIPENDENTE 611
Medullary thyroid carcinoma in children 406
null 259
Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy 257
L’ANALISI GENETICA DI CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE RIVELA LA LORO NATURA CASUALE 207
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 204
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. 203
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 190
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 186
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma 184
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10 years follow up study 177
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 173
Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients 170
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 169
Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland 166
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 163
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 161
null 160
Risk of Differentiated Thyroid Carcinoma and Polymorphisms within the Susceptibility Cancer Region 8q24 160
Advances in the follow-up of differentiated or medullary thyroid cancer. 159
Incidental versus clinically evident thyroid cancer: A 5-year follow-up study 159
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 159
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 158
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 158
null 157
Thyroid carcinoma in thyrotoxic patients treated by surgery. 156
Circulating neuron-specific enolase in medullary thyroid cancer. 156
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 155
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study 154
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 154
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 153
Studies with recombinant autoepitopes of thyroid peroxidase: evidence suggesting an epitope shared between the thyroid and the gastric parietal cell. 152
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. 150
Routine serum calcitonin measurement in the evaluation of thyroid nodules 149
Targeted Therapy in Thyroid Cancer: State of the Art 149
A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure 148
A patient with MEN1 and end‑stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation 148
T cell responses to orbital antigens in thyroid-associated ophthalmopathy. 146
null 145
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 143
Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk. 141
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 141
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 141
Motesanib diphosphate in progressive differentiated thyroid cancer 140
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 140
Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. 139
Thyroid cancer in children and adolescents. 137
Prevalence of papillary thyroid cancer (PTC) in patients affected by medullary thyroid cancer (MTC) 137
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors 137
null 137
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal 136
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 136
Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients 136
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 136
Identification of two distinct molecular subtypes by digital RNA counting of "non-invasive follicular tumour with papillary-like nuclear features (NIFTP)" 134
Serum bone Gla-protein (osteocalcin) in patients with bone metastases from thyroid cancer 133
RET point mutations in Thyroid Carcinoma 133
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 133
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas 132
Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma 132
mRNA and miRNA expression profiling of follicular variant of papillary thyroid carcinoma with and without distant metastases 131
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium 130
CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma 130
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. 130
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 130
Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma 130
Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. 129
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 128
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 127
Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. 126
Association between BRAF V600E mutation and recurrence of papillary thyroid cancer 126
Lack of evidence supporting the presence of mRNA for the thyrotropin receptor in extra-ocular muscle. 125
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 125
Genome-wide association study on differentiated thyroid cancer. 125
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer 125
Evidences that the polymorphism Pro-282-Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma 125
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid 124
Interventional bronchoscopy in the treatment of tracheal obstruction secondary to advanced thyroid cancer 124
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 123
Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients 122
null 122
TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations. 121
Il carcinoma tiroideo: nuove prospettive terapeutiche. 121
A comprehensive meta-analysis of case-control association studies to evaluate polymorphisms associated with the risk of differentiated thyroid carcinoma 121
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 121
Muscle autoantigens in thyroid associated ophthalmopathy: the limits of molecular genetics. 120
Anaplastic thyroid cancer therapy: dream or reality? 120
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer 120
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 120
KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease 119
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 119
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 119
New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. 118
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 118
Demonstration of the existence of the alternatively spliced form of thyroid peroxidase in normal thyroid. 117
Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment 117
Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy 117
Thyroid nodule and differentiated thyroid cancer management in pregnancy. An Italian Association of Clinical Endocrinologists (AME) and Italian Thyroid Association (AIT) Joint Statement for Clinical Practice 117
Thyroid consequences of the Chernobyl nuclear accident. 117
Post-surgical follow-up of differentiated thyroid cancer. 116
Totale 15.060
Categoria #
all - tutte 98.722
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.722


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20193.269 0 0 0 0 0 0 0 136 263 893 1.111 866
2019/20208.563 974 612 540 551 874 945 907 642 779 652 917 170
2020/20213.725 390 248 322 153 295 247 281 325 340 317 246 561
2021/20225.334 124 234 126 379 1.103 698 178 244 286 218 340 1.404
2022/20238.158 975 1.126 612 611 766 911 234 703 1.375 112 564 169
2023/20244.582 716 602 703 441 748 928 287 157 0 0 0 0
Totale 42.737